News & Presentations

UPCOMING EVENTS

CORPORATE PRESENTATIONS

Date Title Documents

Axitinib Implant (AR-14034) Overview

Corporate Presentation – January

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
2020 Net Revenues of $83.1 Million Increased 19% over 2019 Fourth Quarter Net Revenues of $24.7 Million or $80 Per Bottle New Sustained Release Pan-VEGF Inhibitor Pipeline Candidate Announced Today Conference Call and Webcast Today, February 25 th , at 5:00 p.m. ET DURHAM, N.C.
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 22, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 18, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
DURHAM, N.C. --(BUSINESS WIRE)--Jan. 11, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
TOP